NIVABUPA Niva Bupa Health Insurance Company Q3 FY25 results (Oct–Dec 2024) and concall
Niva Bupa Health reported a quarter of transition, dominated by the implementation of the new 1-by-N accounting regulation by the IRDAI. While this impacted reported GWP growth and expense ratios, management emphasized that the underlying business fundamentals and economic value remain unchanged, pointing to a strong 9M IFRS PAT of ₹119.5 crores. The company continued to gain market share in retail health and showed improvement in its like-for-like combined ratio, while progressing on a regulatory glide path to bring its expense of management ratio within the prescribed limits.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 1,321 | 1,258 |
| EBITDA | -66 | -24 |
| Net profit | 13 | 13 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
